• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
75,717.62 318.90
( 0.42%)
Global Indices
Nasdaq
50,087.63 373.42
(0.75%)
Dow Jones
7,522.46 57.21
(0.77%)
Hang Seng
61,141.50 -1,512.55
(-2.41%)
Nikkei 225
10,362.65 37.30
(0.36%)
Forex
USD-INR
95.64 0.03
(0.04%)
EUR-INR
112.06 -0.23
(-0.21%)
GBP-INR
129.33 -0.17
(-0.13%)
JPY-INR
0.61 0.00
(-0.10%)

EQUITY - MARKET SCREENER

Advanced Enzyme Technologies Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
540025
INE837H01020
63.3737836
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ADVENZYMES
30.27
4087.13
EPS(TTM)
Face Value()
Div & Yield %
12.06
2
0.37
 

MCX hits record high after foreign broker upgrade target price
Apr 13,2026
The broker said MCX’s business model benefits from elevated commodity price volatility since the outbreak of the Iran war. Noting that exchange volumes typically rise with a heightened volatility in commodity prices, the bourse is well-positioned as broader decline in Indian equities. Analysts expect strong revenue growth in the current risk-off sentiment.

MCX is India's largest commodity derivatives exchange, with around 98% market share in commodity futures. It offers trading in a diverse range of commodities, spanning multiple segments including bullion, energy, metals and agri commodities, as well as sectoral commodity indices.

The company reported 150.63% year-on-year (YoY) surge in consolidated net profit to Rs 401.12 crore in Q3 FY26, compared with Rs 160.04 crore in Q3 FY25. Income from operations jumped 120.85% YoY to Rs 665.62 crore for the quarter ended 31 December 2025.